Publications

BibTex format

@article{Lavezzo:2022:10.1186/s13073-022-01066-2,
author = {Lavezzo, E and Pacenti, M and Manuto, L and Boldrin, C and Cattai, M and Grazioli, M and Bianca, F and Sartori, M and Caldart, F and Castelli, G and Nicoletti, M and Nieddu, E and Salvadoretti, E and Labella, B and Fava, L and Vanuzzo, MC and Lisi, V and Antonello, M and Grimaldi, CI and Zulian, C and Del, Vecchio C and Plebani, M and Padoan, A and Cirillo, DM and Brazzale, AR and Tonon, G and Toppo, S and Dorigatti, I and Crisanti, A},
doi = {10.1186/s13073-022-01066-2},
journal = {Genome Medicine: medicine in the post-genomic era},
pages = {61--61},
title = {Neutralising reactivity against SARS-CoV-2 delta and omicron variants by vaccination and infection history.},
url = {http://dx.doi.org/10.1186/s13073-022-01066-2},
volume = {14},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The continuous emergence of SARS-CoV-2 variants of concern (VOC) with immune escape properties, such as Delta (B.1.617.2) and Omicron (B.1.1.529), questions the extent of the antibody-mediated protection against the virus. Here we investigated the long-term antibody persistence in previously infected subjects and the extent of the antibody-mediated protection against B.1, B.1.617.2 and BA.1 variants in unvaccinated subjects previously infected, vaccinated naïve and vaccinated previously infected subjects. METHODS: Blood samples collected 15 months post-infection from unvaccinated (n=35) and vaccinated (n=41) previously infected subjects (Vo' cohort) were tested for the presence of antibodies against the SARS-CoV-2 spike (S) and nucleocapsid (N) antigens using the Abbott, DiaSorin, and Roche immunoassays. The serum neutralising reactivity was assessed against B.1, B.1.617.2 (Delta), and BA.1 (Omicron) SARS-CoV-2 strains through micro-neutralisation. The antibody titres were compared to those from previous timepoints, performed at 2- and 9-months post-infection on the same individuals. Two groups of naïve subjects were used as controls, one from the same cohort (unvaccinated n=29 and vaccinated n=20) and a group of vaccinated naïve healthcare workers (n=61). RESULTS: We report on the results of the third serosurvey run in the Vo' cohort. With respect to the 9-month time point, antibodies against the S antigen significantly decreased (P=0.0063) among unvaccinated subjects and increased (P<0.0001) in vaccinated individuals, whereas those against the N antigen decreased in the whole cohort. When compared with control groups (naïve Vo' inhabitants and naïve healthcare workers), vaccinated subjects that were previously infected had higher antibody levels (P<0.0001) than vaccinated naïve subjects. Two doses of vaccine elicited stronger anti-S antibody response than natural infection (P<0.0001). Finally, the neutralising rea
AU  - Lavezzo,E
AU  - Pacenti,M
AU  - Manuto,L
AU  - Boldrin,C
AU  - Cattai,M
AU  - Grazioli,M
AU  - Bianca,F
AU  - Sartori,M
AU  - Caldart,F
AU  - Castelli,G
AU  - Nicoletti,M
AU  - Nieddu,E
AU  - Salvadoretti,E
AU  - Labella,B
AU  - Fava,L
AU  - Vanuzzo,MC
AU  - Lisi,V
AU  - Antonello,M
AU  - Grimaldi,CI
AU  - Zulian,C
AU  - Del,Vecchio C
AU  - Plebani,M
AU  - Padoan,A
AU  - Cirillo,DM
AU  - Brazzale,AR
AU  - Tonon,G
AU  - Toppo,S
AU  - Dorigatti,I
AU  - Crisanti,A
DO  - 10.1186/s13073-022-01066-2
EP  - 61
PY  - 2022///
SN  - 1756-994X
SP  - 61
TI  - Neutralising reactivity against SARS-CoV-2 delta and omicron variants by vaccination and infection history.
T2  - Genome Medicine: medicine in the post-genomic era
UR  - http://dx.doi.org/10.1186/s13073-022-01066-2
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35689243
UR  - https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01066-2
UR  - http://hdl.handle.net/10044/1/97676
VL  - 14
ER  -

Download

DrIlariaDorigatti

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)